Pfizer and Moderna COVID-19 Omicron Boosters Get OK from the FDA
Pfizer and Moderna COVID-19 Omicron Boosters Get OK from the FDA
The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.
The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.
Moderna
FDA Green Lights COVID-19 Vaccines for Kids Under 5
Andy Carstens | Jun 17, 2022 | 2 min read
Moderna and Pfizer-BioNTech shots could be given to the youngest kids as early as June 21.
FDA Limits Use of J&J Vaccine, Citing Safety Concerns
Natalia Mesa, PhD | May 6, 2022 | 2 min read
US adults are now only eligible for the vaccine under certain circumstances.
CDC: COVID-19 Booster Effectiveness Wanes After Four Months
Natalia Mesa, PhD | Feb 14, 2022 | 2 min read
The agency also finds that third shots prevented hospitalizations during the Omicron wave.
Johnson & Johnson Vaccine Garners First Full Approval
Chloe Tenn | Nov 24, 2021 | 1 min read
Health Canada has given the single COVID-19 shot the official greenlight for use in people 18 and older.
Moderna Vaccine Paused for Young People in Two European Countries
Chloe Tenn | Oct 6, 2021 | 3 min read
Health authorities in both countries announced that people under certain age cutoffs are now ineligible for the Spikevax COVID-19 shot due to its association with heart inflammation.
Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?
Alejandra Manjarrez, PhD | Sep 24, 2021 | 10 min read
Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.
Wealthier Nations Disregarding WHO Call for COVID-19 Booster Moratorium
Christie Wilcox, PhD | Aug 5, 2021 | 3 min read
The organization implored nations to wait on booster shots until the global vaccination rate increases, but several of the world’s more well-off countries have expressed their intentions to offer them regardless.
COVID-19 Vaccines Appear Safe During Pregnancy: Early Data
Christie Wilcox, PhD | Apr 22, 2021 | 2 min read
Scientists at the US CDC report no red flags in a preliminary analysis of the safety of Pfizer/BioNTech’s and Moderna’s mRNA-based immunizations among expectant mothers.
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Shawna Williams | Apr 16, 2021 | 3 min read
The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021 | 6 min read
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
US Authorizes a Third COVID-19 Vaccine
Asher Jones | Mar 1, 2021 | 2 min read
Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.
One-Shot COVID-19 Vaccine Prevents Severe Disease
Asher Jones | Jan 29, 2021 | 2 min read
Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.
Moderna Developing Booster Shot for New Virus Variant B.1.351
Asher Jones | Jan 25, 2021 | 2 min read
New data suggest that the company’s approved COVID-19 vaccine protects against different virus variants, but could be less effective against the one that originated in South Africa.
US Officials Debate Efficacy of Half Doses of COVID-19 Vaccine
Lisa Winter | Jan 5, 2021 | 3 min read
The head of Operation Warp Speed says that by spreading out doses of the Moderna vaccine, more people would be able to get some level of protection sooner, a strategy opposed by other experts.
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Max Kozlov | Nov 16, 2020 | 3 min read
The results mark the second experimental COVID-19 vaccine to show high efficacy, but the study is not complete and the data have not been peer reviewed.